Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial

Sean W. Willemse,Kit C. B. Roes,Philip Van Damme,Orla Hardiman,Caroline Ingre,Monica Povedano,Naomi R. Wray,Marleen Gijzen,Mirjam S. de Pagter,Koen C. Demaegd,Annemarie F. C. Janse,Roel G. Vink,Boudewijn T. H. M. Sleutjes,Adriano Chiò,Philippe Corcia,Evy Reviers,Ammar Al-Chalabi,Matthew C. Kiernan,Leonard H. van den Berg,Michael A. van Es,Ruben P. A. van Eijk
DOI: https://doi.org/10.1186/s13063-022-06906-5
IF: 2.728
2022-12-06
Trials
Abstract:Given the large genetic heterogeneity in amyotrophic lateral sclerosis (ALS), it seems likely that genetic subgroups may benefit differently from treatment. An exploratory meta-analysis identified that patients homozygous for the C-allele at SNP rs12608932, a single nucleotide polymorphism in the gene UNC13A , had a statistically significant survival benefit when treated with lithium carbonate. We aim to confirm the efficacy of lithium carbonate on the time to death or respiratory insufficiency in patients with ALS homozygous for the C-allele at SNP rs12608932 in UNC13A .
medicine, research & experimental
What problem does this paper attempt to address?